{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+Calcitonin+Tablets",
    "query": {
      "intervention": "Oral Calcitonin Tablets"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-12T07:38:56.575Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05895500",
      "title": "Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Dry Eye",
        "Asthenopia"
      ],
      "interventions": [
        {
          "name": "Injection for SC administration (120mg/syringe)",
          "type": "DRUG"
        },
        {
          "name": "Tablet (50mg/tablet), oral",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nvision Laser Eye Centers",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2023-05-10",
      "completion_date": "2023-11-09",
      "has_results": false,
      "last_update_posted_date": "2024-06-03",
      "last_synced_at": "2026-09-12T07:38:56.575Z",
      "location_count": 1,
      "location_summary": "Torrance, California",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05895500"
    },
    {
      "nct_id": "NCT00620854",
      "title": "A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "Recombinant Salmon Calcitonin (rsCT)",
          "type": "DRUG"
        },
        {
          "name": "Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Nasal Spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tarsa Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 70 Years · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2008-02",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2012-02-01",
      "last_synced_at": "2026-09-12T07:38:56.575Z",
      "location_count": 1,
      "location_summary": "Springfield, Missouri",
      "locations": [
        {
          "city": "Springfield",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00620854"
    },
    {
      "nct_id": "NCT05217927",
      "title": "Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Rimegepant 75mg daily dosing",
          "type": "DRUG"
        },
        {
          "name": "Rimegepant 75mg every other day dosing",
          "type": "DRUG"
        },
        {
          "name": "Placebo comparator dosing",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1415,
      "start_date": "2022-03-04",
      "completion_date": "2024-12-11",
      "has_results": true,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-09-12T07:38:56.575Z",
      "location_count": 30,
      "location_summary": "Tempe, Arizona • Colton, California • Los Angeles, California + 27 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05217927"
    },
    {
      "nct_id": "NCT00959764",
      "title": "A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoporosis, Postmenopausal"
      ],
      "interventions": [
        {
          "name": "Oral Calcitonin Tablets",
          "type": "DRUG"
        },
        {
          "name": "Intranasal Calcitonin",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablets and placebo intranasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tarsa Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "45 Years and older · Female only"
      },
      "enrollment_count": 565,
      "start_date": "2009-06",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2013-11-19",
      "last_synced_at": "2026-09-12T07:38:56.575Z",
      "location_count": 9,
      "location_summary": "Huntsville, Alabama • Oakland, California • Palm Desert, California + 6 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00959764"
    },
    {
      "nct_id": "NCT01292187",
      "title": "A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteopenia"
      ],
      "interventions": [
        {
          "name": "Oral calcitonin at dinnertime",
          "type": "DRUG"
        },
        {
          "name": "Oral placebo at dinnertime",
          "type": "DRUG"
        },
        {
          "name": "Oral calcitonin at bedtime",
          "type": "DRUG"
        },
        {
          "name": "Oral placebo at bedtime",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tarsa Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "45 Years and older · Female only"
      },
      "enrollment_count": 129,
      "start_date": "2011-01",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2014-09-12",
      "last_synced_at": "2026-09-12T07:38:56.575Z",
      "location_count": 10,
      "location_summary": "Walnut Creek, California • Clearwater, Florida • Bethesda, Maryland + 7 more",
      "locations": [
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01292187"
    },
    {
      "nct_id": "NCT03898856",
      "title": "Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Diarrhea of Unknown Origin"
      ],
      "interventions": [
        {
          "name": "Crofelemer",
          "type": "DRUG"
        },
        {
          "name": "Diagnostic tests for cause of chronic diarrhea",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 93,
      "start_date": "2019-04-01",
      "completion_date": "2025-01-30",
      "has_results": true,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-09-12T07:38:56.575Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03898856"
    },
    {
      "nct_id": "NCT01329562",
      "title": "CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Menstrual Migraine"
      ],
      "interventions": [
        {
          "name": "Treximet",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cady, Roger, M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 41,
      "start_date": "2011-05",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2014-04-09",
      "last_synced_at": "2026-09-12T07:38:56.575Z",
      "location_count": 2,
      "location_summary": "Springfield, Missouri • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01329562"
    },
    {
      "nct_id": "NCT00803686",
      "title": "A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Phase 1 Pharmacodynamic Study"
      ],
      "interventions": [
        {
          "name": "Oral rsCT tablet",
          "type": "DRUG"
        },
        {
          "name": "Oral Placebo Tablet",
          "type": "DRUG"
        },
        {
          "name": "Fortical (rsCT) nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tarsa Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 70 Years · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2008-12",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2014-06-09",
      "last_synced_at": "2026-09-12T07:38:56.575Z",
      "location_count": 1,
      "location_summary": "Springfield, Missouri",
      "locations": [
        {
          "city": "Springfield",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00803686"
    }
  ]
}